Cytokine News and Research

RSS

Ability to defend against environmental stress may affect longevity

A shorter life may be the price an organism pays for coping with the natural assaults of daily living, according to researchers at the National Institutes of Health and their colleagues in Japan.

21 Dec 2017

Study findings could lead to less expensive and more effective cancer treatments

The latest generation of cancer treatments spring from the discovery that the human immune system is able to beat the disease. Like Dorothy in "The Wizard of Oz," what research teams around the world have spent decades searching for was right in their own backyard all along.

20 Dec 2017

Researchers identify mechanism that regulates signaling events leading to cancer metastasis

Understanding how cancer cells are able to metastasize -- migrate from the primary tumor to distant sites in the body -- and developing therapies to inhibit this process are the focus of many laboratories around the country.

18 Dec 2017

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

11 Dec 2017

Two immunotherapy approaches for multiple myeloma show hope

Researchers from the University of Pennsylvania's Abramson Cancer Center have developed two experimental immunotherapy methods that include one chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma patients who were not responding to other treatments.

11 Dec 2017

Study finds mechanism of resistance to checkpoint inhibitors and way to reverse it

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

8 Dec 2017

Clearance of cancer cell debris via pro-resolving mediators can prevent tumor recurrence

Cancer therapies are designed to kill tumor cells, but produce tumor cell debris in the process. In a study published in The Journal of Experimental Medicine, researchers from Brigham and Women's Hospital and colleagues show that leftover debris can stimulate inflammation and tumor growth, but that molecules called resolvins can block that unwanted inflammatory response.

5 Dec 2017

Chemotherapy-generated debris from dead and dying cancer cells can stimulate tumor growth

Cancer therapies including radiation and chemotherapy seek to treat the disease by killing tumor cells. Now a team including researchers at Beth Israel Deaconess Medical Center have shown that the dead and dying cancer cells generated by chemotherapy and targeted cancer therapy paradoxically trigger inflammation that promotes aggressive tumor growth.

1 Dec 2017

UNC Lineberger professor receives The Leukemia & Lymphoma Society grant for immunotherapy research

UNC Lineberger Comprehensive Cancer Center researcher Barbara Savoldo, MD, PhD, was awarded a $600,000, three-year grant from The Leukemia & Lymphoma Society to support research into an immunotherapy treatment being developed with a "safety switch" to safeguard against potential side effects of the treatment.

21 Nov 2017

‘Chemo brain’ may start as tumors form and develop, suggests study

The memory and thinking problems experienced by cancer survivors, known as "chemo brain" or "chemo fog," are not just the result of chemotherapy treatment, they may start as tumors form and develop, suggests a Baycrest-led study.

21 Nov 2017

Researchers identify new way to reduce risk of complications after joint surgery

Researchers identified a new way to lower the risk of complications after joint surgery, using a simple blood test. Patients with diabetes are more likely to need joint replacement surgery but also have a greater risk of serious complications after surgery, including heart attack, stroke, and wound infections, because of their underlying diabetes.

16 Nov 2017

Ozanimod effective against multiple sclerosis, enters New Drug Approval process with FDA

Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod.

10 Nov 2017

Scientists uncover mechanism that prevents tumor growth in melanoma

Natural Killer (NK) cells, lymphocytes of the innate immune system with strong cytotoxic activity, play a major role in the immune response against tumors.

8 Nov 2017

Gut bacteria can influence how cancer responds to immunotherapy

Bacteria that live in the human digestive tract can influence how cancer responds to immunotherapy, opening a new avenue for research to improve treatment, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the journal Science.

2 Nov 2017

Conference to focus on preventing and reversing consequences of sickle cell disease

Leading experts in the field of sickle cell disease (SCD) research will convene in Washington, D.C., for the Physiological and Pathophysiological Consequences of Sickle Cell Disease conference (November 6–8). The conference, organized by the American Physiological Society, will explore SCD- the world's most prevalent single-gene mutation disease - and new research on preventing and reversing its deadly consequences.

1 Nov 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

Cascade of costs could push new gene therapy above $1 million per patient

Outrage over the high cost of cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country's first gene therapy, Novartis' Kymriah, a leukemia treatment approved in August.

17 Oct 2017

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

Maternal immune activation linked to ASD symptom severity in children with autism

The retrospective cohort study of 220 Australian children, conducted between 2011-2014, indicates that a "an immune-mediated subtype" of autism driven by the body's inflammatory and immunological systems may be pivotal, according to the University of Sydney's Professor Adam Guastella.

10 Oct 2017

CRISPR-Gold corrects gene mutations in mice with Duchenne muscular dystrophy

Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR-Cas9 gene-editing technology inside cells and have demonstrated in mice that the technology can repair the mutation that causes Duchenne muscular dystrophy, a severe muscle-wasting disease.

4 Oct 2017